A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

por Ngoi, Natalie YL, Heong, Valerie, Ow, Samuel, Chay, Wen Yee, Kim, Hee Seung, Choi, Chel Hun, Goss, Geraldine, Goh, Jeffrey C, Tai, Bee Choo, Lim, Diana GZ, Kaliaperumal, Nivashini, Au, Veonice B, Connolly, John E, Kim, Jae-Weon, Friedlander, Michael, Kim, Kidong, Tan, David SP
Publicado 2020

First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults

por Prativadibhayankaram, Venkateshan S., Lee, Lawrence Soon-U, Lye, David, Xiaoying, Xu, Nellore, Ranjani, Pendharkar, Vishal, Hentze, Hannes, Guan, Siyu, Ayers, Benjamin J., Seah, Shirley G. K., Chye, De Hoe, Talib, Najwa S. N., Kaliaperumal, Nivashini, Ong, Wei Yee, Wong, Zi Xin, Au, Veonice B., Alok, Anshula, Connolly, John E., Boyd-Kirkup, Jerome D., Ingram, Piers J., Hanson, Brendon J., Ethirajulu, Kantharaj, O’Connell, Damian, Chan, Conrad E. Z.
Publicado 2022